282例乳腺癌临床与免疫组化指标的相关性分析  

Correlation analysis of 282 cases of breast cancer with immunohistochemical index

作　　者：张睿[1] 范永红[1] 

机构地区：[1]内蒙古包头市中心医院普外四科,内蒙古包头014040

出　　处：《世界最新医学信息文摘》2013年第3期26-27,共2页World Latest Medicine Information Electronic Version

摘　　要：目的分析免疫组化指标在乳腺癌组织中的表达,并探讨其与临床病理因素之间的相关性及意义.方法用免疫组化法检测282例乳腺癌患者病理组织中Ki-67、C-erbB-2、P53、VEGF的表达,并结合临床病理因素进行相关性分析.结果在282例乳腺癌组织中,Ki-67、C-erbB-2、P53、VEGF的阳性表达率分别为75.9%、61.0%、58.9%、57.1%.Ki-67的表达与乳腺癌临床分期显著相关,且与P53、C-erbB-2表达呈正相关.结论乳腺癌组织中Ki-67、C-erbB-2、P53、VEGF的表达有一定的相关性,联合检测有助于指导该类肿瘤的治疗.Objective Analysis of the expression of immunohistochemical markers in breast cancer tissues, and to explore the correlation and significance between them and the clinical pathological factors. Methods the expression by immunohistochemistry in 282 cases of breast cancer were detected in Ki-67, C-erbB-2, P53, VEGF, and combined with the clinical pathological factors by correlation analysis.Results in 282 cases of breast cancer tissues, the positive expression of Ki-67, C-erbB-2, P53, VEGF were 75.9%, 61%, 58.9%, 57.1%. The expression of Ki-67 was significantly associated with clinical stage of breast cancer, and was positively correlated with P53, C-erbB-2 expression. Conclusion there is a correlation between the expression of Ki-67 in breast cancer tissues, C-erbB-2, P53, VEGF, helps to guide the treatment of combined detection of the tumor.

关 键 词：乳腺癌 免疫组化指标 病理特征 

分 类 号：R737.9[医药卫生—肿瘤]